A prospective observational study of T cell subsets after administration of immune checkpoint inhibitors in patients with lung cancer

A prospective observational study of T cell subsets after administration of immune checkpoint inhibitors in patients with lung cancer - pharmacodynamics analysis based on T cell subsets of immune checkpoint inhibitors in patients with lung cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043565

Enrollment

Registered

2021-03-09

Start date

2020-10-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 years or older 2) Lung cancer patients 3) Scheduled to be treated with an immune checkpoint inhibitor. 4) Written consent has been obtained.

Exclusion criteria

Exclusion criteria: inappropriate by the investigator and the investigator

Design outcomes

Primary

Measure	Time frame
Changes in T cell subsets	—

Countries

Japan

Contacts

Public ContactKei Irie

Kobe Gakuin University Faculty of Pharmaceutical Science

kei_irie@pharm.kobegakuin.ac.jp078-974-1551

Outcome results